Adjuvant chemotherapy for early breast cancer: Optimal use of epirubicin

Oncologist

Volumn 10, Issue 10, 2005, Pages 780-791

  Glück, Stefan ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Adjuvant treatment; Anthracyclines; Doxorubicin; Epirubicin; Neoadjuvant treatment

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAMOXIFEN CITRATE; TAXANE DERIVATIVE; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG UTILIZATION; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEMATOLOGIC DISEASE; HUMAN; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EPIRUBICIN; FEMALE; HUMANS; PACLITAXEL; TAXOIDS;

EID: 31444432285     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.10-10-780     Document Type: Review

References (59)

1. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-410.
2. Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-942.
3. Carpenter JT, Velez-Garcia E, Aron BS et al. Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer: a Southeastern Cancer Study Group study. Proc Am Soc Clin Oncol 1994;13:66.
4. Martin M, Villar A, Sole-Calvo A et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 2003;14:833-842.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
6. Coombes RC, Bliss JM, Wils J et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 1996;14:35-45.
7. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602-611.
8. Bonneterre J, Roche H, Kerbrat P et al. French Adjuvant Study Group 05 trial (FEC 50 vs FEC 100): 10-year update of benefit/risk ratio after adjuvant chemotherapy (CT) in node-positive (N+), early breast cancer (EBC) patients (pts). Proc Am Soc Clin Oncol 2003;22:24.
9. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
10. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998;16:2651-2658.
11. Bonneterre J, Roche H, Kerbrat P et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-Year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005;23:2686-2693.
12. Pritchard KI, Levine MN, Bramwell VHC et al. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA.5. Breast Cancer Res Treat 2002;S33.
13. Poole CJ, Hear HM, Dunn JA et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc Am Soc Clin Oncol 2003;22:4.
14. Mouridsen H, Andersen J, Andersson M et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 1999;18:68a.
15. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906.
16. Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-1211.
17. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246-2257.
18. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. The Oncologist 2001;6(suppl 3):30-35.
19. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
20. Berry DA, Cirrincione C, Henderson IC et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res Treat 2004;88:S17.
21. Möbus VJ, Untch M, Du Bois A et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥4+LN). First results of an AGO-trial. Proc Am Soc Clin Oncol 2004; Late-Breaking Abstracts Book:14.
22. Untch M, Thomssen C, Steffen K et al. Five year results of a randomised multicenter dose intense (DI-EC) study with epirubicin (E) and cyclophosphamide (C) in high-risk breast cancer patients - a treatment of short duration with comparable efficacy to conventional chemotherapy. San Antonio Breast Cancer Symposium 2002. Breast Cancer Res Treat 2002;76:S158.
23. Martin M, Pienkowski T, Mackey J et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;43a.
24. Roché H, Fumoleau P, Spielmann M et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium 2004. Breast Cancer Res Treat 2004;88:S16.
25. Eggemann H, Krocker J, Kuemmel S et al. Sequential dose-dense epirubicin/paclitaxel (E-T) with G-CSF support compared to standard EC - T (epirubicin/cyclophosphamide followed by paclitaxel) for patients with operable breast cancer and 1-3 positive nodes-first toxicity analysis. San Antonio Breast Cancer Symposium 2002. Breast Cancer Res Treat 2002;76:S159.
26. Paik S, Bryant J, Tan-Chiu E et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-1998.
27. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266.
28. Thor AD, Berry DA, Budman DR et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-1360.
29. Sanchez-Rovira P, Duenas B, Cidraque M et al. Dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab as neoadjuvant chemotherapy in stage II and III breast cancer. A phase II and pharmacogenomic study. Proc Am Soc Clin Oncol 2004;23:29.
30. Valero V, Gill E, Paton YH et al. Normal cardiac biopsy results following co-administration of doxorubicin (A), cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer. Proc Am Soc Clin Oncol 2004;23:20.
31. Untch M, Eidtmann H, du Bois A et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 2004;40:988-997.
32. Buzdar AU, Hunt K, Smith D et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. Proc Am Soc Clin Oncol 2004;23:7.
33. Fargeot P, Roche H, Bonneterre JM et al. Disease-free survival (DFS) advantage of weekly epirubicin plus tamoxifen vs tamoxifen (Tam) alone as adjuvant treatment of operable, node-positive (N+) elderly breast cancer (BC) patient (pts): 5-year follow-up results of French Adjuvant Study Group, FASG-08 trial. Proc Am Soc Clin Oncol 2002;21:37a.
34. Norton L, Slamon D, Leyland-Jones B et al. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1999;18:127a.
35. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
36. Romond E. Joint analysis of NSABP-B-31 and NCCTG-N9831. Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Track: Breast Cancer (Disease-Specific Tracks). Session: Advances in Monoclonal Antibody Therapy for Breast Cancer (Scientific Symposium). Sledge GW Jr, chair. Available at http://www.asco.org/ac/1,1003,_ 12-002514-00_18-0034-00_19-00934-00_21-001,00. asp. Accessed October 31, 2005.
37. Piccart-Gebhart MJ. HERA trial. Presented at the 2005 American Society of Clinical Oncology Annual Meeting. Track: Breast Cancer (Disease-Specific Tracks). Session: Advances in Monoclonal Antibody Therapy for Breast Cancer (Scientific Symposium). Sledge GW Jr, chair. Available at http://www.asco.org/ ac/1,1003,_12-002514-00_18-0034-00_19-00934-00_21-001,00.asp. Accessed October 31, 2005.
38. Smith RE, Bryant J, DeCillis A et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 2003;21:1195-1204.
39. Diamandidou E, Buzdar AU, Smith TL et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 1996;14:2722-2730.
40. Albain K, Green S, Ravdin P et al. Overall survival after cyclophosphamide, Adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: new findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100). Proc Am Soc Clin Oncol 2001;20:94a.
41. Fumoleau P, Roche H, Kerbrat P et al. Long-term benefit/risk ratio of epirubicin (EPI)-based adjuvant chemotherapy (CT) in operable breast cancer (BC) patients (pts): 7-year analysis in 3577 pts of French Adjuvant Study Group (FASG) trials. Proc Am Soc Clin Oncol 2003;22:23.
42. Praga C, Bergh J, Bliss J et al. Risk of myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005;23:4179-4191.
43. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993;19:197-228.
44. Perez EA, Suman VJ, Davidson NE et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2004;22:3700-3704.
45. Ryberg M, Nielsen D, Skovsgaard T et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998;16:3502-3508.
46. Bonneterre J, Roche H, Kerbrat P et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol 2004;22:3070-3079.
47. Gluck S. The expanding role of epirubicin in the treatment of breast cancer. Cancer Control 2002;9(suppl):16-27.
48. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-329.
49. Buzdar AU, Hunt K, Smith T et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. Proc Am Soc Clin Oncol 2004;23:7.
50. Perez EA, Suman VJ, Davidson NE et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Proc Am Soc Clin Oncol 2005;23:17s.
51. Independent Data Monitoring Committee. 4th Cardiac Safety Analysis. Presented at the Breast Cancer International Research Group Investigators' Meeting held at the American Society of Clinical Oncology Annual Meeting, May 13, 2005. Slamon D, co-chair. Available at http://www.bcirg.org/Internet/ Studies/BCIRG+006.htm. Accessed October 31, 2005.
52. Minotti G, Licata S, Saponiero A et al. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4FE-4S] reactivity of its secondary alcohol metabolite. Chem Res Toxicol 2000;13:1336-1341.
53. Salvatorelli E, Gianni L, Marsoni S et al. Formation of toxic anthracycline secondary alcohol metabolites in human myocardium: comparison between doxorubicin and epirubicin and effects of paclitaxel, docetaxel, and the epithilones BMS310705 and BMS247550. Proc Am Assoc Cancer Res 2004;45:1254.
54. National Surgical Adjuvant Breast and Bowel Project. NSABP Clinical Trials Overview. Protocol 36. Available at http://www.nsabp.pitt.edu/B-36.htm. Accessed October 31, 2005.
55. Saskatchewan Cancer Agency. National Cancer Institute Clinical Trials Group, North Central Cancer Treatment Group and Drug Company Activated And Approved Clinical Trials At The Allan Blair Cancer Centre. Available at http://www.scf.sk.ca/dept/ClinicalTrials/ClinicalTrials_ June_04.htm. Accessed October 31, 2005.
56. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubi- cincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1485-1496.
57. Sartor CI, Peterson BL, Woolf S et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol 2005;23:30-40.
58. Wils JA, Bliss JM, Marty M et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol 1999;17:1988-1998.
59. Mouridsen HT, Andersen J, Andersson M et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 1999;18:68a.